Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD…
$103.86+7.53%
报价 2026-11-06
市值
$9.59B
EV
$8.95B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -4.6%
$22.18$108.92
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | $9.59B | +7.5% | 0.0% | 0% | – | – | – | |
| ABCLAbCellera Biologics Inc. | $3.85B | +6.7% | – | 75% | – | – | – | |
| PHVSPharvaris N.V. | $2.4B | +5.7% | – | 0% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.35B | +5.7% | -11.1% | 100% | – | – | – | |
| IMNMImmunome, Inc. | $2.21B | +4.5% | -67.5% | -1,161.9% | – | – | – | |
| ZYMEZymeworks Inc. | $2.13B | +3.1% | – | 98.4% | – | – | – | |
| MAZEMaze Therapeutics, Inc. | $1.9B | +5.1% | +545.2% | 95.3% | – | – | – | |
| NTLAIntellia Therapeutics, Inc. | $1.59B | +2.3% | +5.3% | -46.5% | – | – | – | |
| ARDXArdelyx, Inc. | $717.7M | -3.7% | +36.3% | 90.3% | – | – | – | |
| 同行中位数 | – | – | +5.3% | 82.6% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。